May 26 (UPI) --Researchers at Mount Sinai School of Medicine say a new study shows how a treatment commonly used for insomnia can assist in calming a potentially violent sleeping disorder in which ...

TOKYO, May 28, 2025 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in ...

TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data ...

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with ...

June 13, 2012 (Boston, Massachusetts) — The investigational dual orexin receptor antagonist suvorexant (Merck) improved sleep onset and maintenance over a 3-month treatment period in 2 pivotal phase 3 ...

Indivior has paid 15.95 million pounds sterling ($20.4 million) to C4X Discovery for the full rights to the British biotech’s orexin-1 receptor antagonist being developed for substance use disorder.

NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profile Sosei ...

ZURICH, Sept 2 (Reuters) - Swiss biotech firm Actelion's experimental sleep drug, the first of a new class of potential medicines, significantly improved sleep for insomniacs in mid-stage clinical ...

Tsukuba, Japan—Orexin, named after its role in feeding regulation, is a potent endogenous sleep/wake state regulator and is expected to play an essential role in controlling the cross-talk mechanism ...